Articles
Boston, MA-Rociletinib, a specially engineered third-generation EGFR inhibitor, is accumulating an impressive track record in early studies of non-small-cell lung cancer (NSCLC). The drug is specifically designed for use in patients with NSCLC and the T790M mutation, a heretofore patient population with unmet needs. T790M, the most common mutation associated with resistance to first-line EGFR-directed tyrosine kinase inhibitor (TKI) therapy, is present in 60% of patients with resistance to TKIs. Read More ›
As a healthcare professional with substantial income-or income potential, you will most likely be contacted by a number of individuals offering various types of financial products and services throughout your career. Read More ›
Elotuzumab (Empliciti) (elotuzumab) has been approved for use in combination with lenalidomide (Revlimid) and dexamethasone in patients with multiple myeloma who have received 1 to 3 prior medications. Daratumumab (Darzalex) is the only other US Food and Drug Administration-approved monoclonal antibody for patients with this type of cancer.
Read More ›
Necitumumab (Portrazza) has been approved in combination with 2 forms of chemotherapy for patients with metastatic, squamous non–small-cell lung cancer (NSCLC) who have not received previous treatment for their cancer.
Read More ›
Copenhagen, Denmark-Intravenous (IV) iron isomaltoside 1000 (Monofer) demonstrated sustained increases in hemoglobin (Hb) and fewer adverse events compared with oral iron sulphate in patients with chemotherapy-induced anemia (CIA), according to research presented by Gunnar Birgegard, MD, PhD, and colleagues at the 2015 Multinational Association of Supportive Care in Cancer/International Society of Oral Oncology Annual Meeting on Supportive Care in Cancer. Read More ›
Hollywood, FL-At the National Comprehensive Cancer Network 20th Annual Conference, Mario E. Lacouture, MD, Associate Professor of Dermatology at Weill Cornell Medical College, and an Associate Attending Physician at Memorial Sloan Kettering Cancer Center, New York, NY, presented some clinical pearls that can guide the management of dermatologic toxicities. Read More ›
Anders Mellemgaard, MD, Medical Oncologist from the Department of Oncology, Herlev University Hospital, Herlev, Denmark, spoke with The Oncology Pharmacist about his study, "Antiangiogenic-Specific Adverse Events in Patients with Non-Small-Cell Lung Cancer Treated with Nintedanib and Docetaxel," regarding the development of the new compound that is augmenting the effect of chemotherapy by treating the new vasculature. Read More ›
By Chase Doyle
Two pilot programs have shown success in raising awareness of safety concerns aimed at reducing the utilization of inappropriate testosterone replacement therapy. Read More ›
The FDA approved sonidegib for all patients with locally advanced basal-cell carcinoma (BCC). Read More ›
In order to navigate the increasingly collaborative healthcare landscape, pharmacists need to find a place at the table, according to a presentation at the annual Hematology/Oncology Pharmacy Association conference. Read More ›